Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
Authors:
- Sami KoltaSKSami Kolta
- Lambert AssoumouLALambert Assoumou
- Jade GhosnJGJade Ghosn
- Sylvie RozenbergSRSylvie Rozenberg
- Robert L MurphyRMRobert L Murphy
- Christine KatlamaCKChristine Katlama
- Dominique CostagliolaDCDominique Costagliola
- 27 April 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (7) , 817-824
Abstract
To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial. Antiretroviral-naive patients were randomized (2: 1: 1) into three treatment strategy arms: a nonnucleoside reverse transcriptase inhibitor (NNRTI) and a boosted protease inhibitor (PI/r), a PI/r and two nucleoside reverse transcriptase inhibitors (NRTIs) or an NNRTI and NRTIs. Hip and lumbar spine standardized BMD were evaluated at baseline and week 48 by dual X-ray absorptiometry by a central reading laboratory. Seventy-one patients were enrolled: 36 in the PI/r and NNRTI, 19 in the PI/r and NRTIs and 16 in the NNRTI and NRTIs arms. Baseline characteristics were [median (interquartile range)]: male (77%), age 40 years (33–49), 69% white, 58% smokers, BMI 23 kg/m2 (21–24), CD4 cell count 219 cells/μl (144–285). In the arms with NRTIs, 86% of patients received zidovudine/lamivudine. At baseline, 31% had osteopenia and 3% had osteoporosis. At week 48, there was a mean change in BMD of −4.1 ± 3.9% at lumbar spine and −2.8 ± 4.7% at hip (both P≤ 0.001). The decrease of BMD at lumbar spine was significantly worse in the PI/r and NNRTI arm (−4.4 ± 3.4%) and in the PI/r and NRTIs arm (−5.8 ± 4.5%) compared with the NNRTI and NRTIs arm (−1.5 ± 2.9%), P = 0.007 and P = 0.001, respectively. BMD was impaired in 34% of patients, before starting any antiretrovirals. After 1 year, the decrease in lumbar spine BMD was more pronounced in patients receiving either PI/r-containing regimen compared with NNRTI and NRTIs. BMD at specific sites should be monitored during lifelong antiretroviral therapy.Keywords
This publication has 40 references indexed in Scilit:
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 2008
- RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV‐1‐positive menJournal of Medical Virology, 2007
- Bone Disease and HIV InfectionClinical Infectious Diseases, 2006
- Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAARTBiomedicine & Pharmacotherapy, 2004
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLOS Medicine, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- BMD Is Reduced in HIV-Infected Men Irrespective of TreatmentJournal of Bone and Mineral Research, 2004
- Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapyAIDS, 2003
- Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsClinical Infectious Diseases, 2003
- Select HIV Protease Inhibitors Alter Bone and Fat Metabolism ex VivoJournal of Biological Chemistry, 2002